Entry Detail


General Information

Database ID:TRD01616
Confidence:High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:tRF-19-W4PU732S
tsRNA Type:i-tRF;tRF-5
Amino acid and Anticodon:SerAGA;SerTGA
Sequence:TCGTGGCCGAGTGGTTAAG
Related Target:RPL27A
Predicted Target:THBS2//UBE2J2//ARHGEF2//CNRIP1//PPIF//PLA2G6//UPB1//PCNX1//TCF23//MYO7B
External Links:
MINTbase ID:tRF-19-W4PU732S
tRFdb ID:N/A

[1] gtRNAdb_ID:tRNA-Ser-AGA-4-1
Anticodon:SerAGA
tRNA_number:trna145
Chromosome:6
Strand:-
Coordinate:Start Site(bp): 27521251        End Site(bp): 27521269

[2] gtRNAdb_ID:tRNA-Ser-AGA-3-1
Anticodon:SerAGA
tRNA_number:trna50
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 27499991        End Site(bp): 27500009

[3] gtRNAdb_ID:tRNA-Ser-AGA-2-6
Anticodon:SerAGA
tRNA_number:trna35
Chromosome:17
Strand:-
Coordinate:Start Site(bp): 8129987        End Site(bp): 8130005

[4] gtRNAdb_ID:tRNA-Ser-AGA-2-2
Anticodon:SerAGA
tRNA_number:trna44
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 27446595        End Site(bp): 27446613

[5] gtRNAdb_ID:tRNA-Ser-AGA-2-3
Anticodon:SerAGA
tRNA_number:trna46
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 27463597        End Site(bp): 27463615

[6] gtRNAdb_ID:tRNA-Ser-AGA-2-4
Anticodon:SerAGA
tRNA_number:trna47
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 27470822        End Site(bp): 27470840

[7] gtRNAdb_ID:tRNA-Ser-AGA-2-1
Anticodon:SerAGA
tRNA_number:trna5
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 26327821        End Site(bp): 26327839

[8] gtRNAdb_ID:tRNA-Ser-AGA-2-5
Anticodon:SerAGA
tRNA_number:trna11
Chromosome:8
Strand:-
Coordinate:Start Site(bp): 96281944        End Site(bp): 96281962

[9] gtRNAdb_ID:tRNA-Ser-AGA-1-1
Anticodon:SerAGA
tRNA_number:trna147
Chromosome:6
Strand:-
Coordinate:Start Site(bp): 27509613        End Site(bp): 27509631

[10] gtRNAdb_ID:tRNA-Ser-TGA-4-1
Anticodon:SerTGA
tRNA_number:trna148
Chromosome:6
Strand:-
Coordinate:Start Site(bp): 27473666        End Site(bp): 27473684

[11] gtRNAdb_ID:tRNA-Ser-TGA-3-1
Anticodon:SerTGA
tRNA_number:trna172
Chromosome:6
Strand:-
Coordinate:Start Site(bp): 26312883        End Site(bp): 26312901

[12] gtRNAdb_ID:tRNA-Ser-TGA-2-1
Anticodon:SerTGA
tRNA_number:trna51
Chromosome:6
Strand:+
Coordinate:Start Site(bp): 27513472        End Site(bp): 27513490



tsRNA Association Statistics

Total Associated Disease Number:1
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D001943DOID:1612
Disease Name:Breast Neoplasmsbreast cancer
Category:MeSHDisease Ontology
Type:Neoplasms//Skin and Connective Tissue Diseasesdisease of anatomical entity//disease of cellular proliferation
Define:Tumors or cancer of the human BREAST.A thoracic cancer that originates in the mammary gland.
Alias:Breast Cancer//Breast Carcinoma//Breast Tumors//Cancer of Breast//Cancer of the Breast//Human Mammary Carcinoma//Malignant Neoplasm of Breast//Malignant Tumor of Breast//Mammary Cancer//Mammary Carcinoma, Human//Mammary Neoplasm, Human//Mammary Neoplasms, Human//Neoplasms, Breast//Tumors, Breastbreast tumor//malignant neoplasm of breast//malignant tumor of the breast//mammary cancer//mammary neoplasm//mammary tumor//primary breast cancer



Disease Association Statistics

Total Associated tsRNA Number:549
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:RT-PCR//Western blot
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:35030975
Disease Name:Breast Neoplasms
Tissue:Breast
Dysfunction Pattern:Up-Regulation
Validated Method:RT-PCR//Western blot//High-throughput sequencing
Description:Our data revealed that tRF-19-W4PU732S was up-regulated in BC, and promoted malignant activity in BC.
Comparision:Cancer VS Normal
Mechanism:In conclusion, our results manifested that tRF-19-W4PU732S promotes the malignant activity of BC cells by inhibiting RPL27A, which provides a new scientific basis for the treatment of BC.